Ciglitazone
CAS: 74772-77-3
Ref. 3D-FC20431
1mg | Descatalogado | ||
2mg | Descatalogado | ||
5mg | Descatalogado | ||
10mg | Descatalogado | ||
25mg | Descatalogado |
Información del producto
- (+/-)-5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dioneADD-3878
- (+-)-5-(p-((1-Methylcyclohexyl)methoxy)benzyl)-2,4-thiazolidinedione
- 2,4-Thiazolidinedione, 5-((4-((1-methylcyclohexyl)methoxy)phenyl)methyl)-, (+-)-
- 5-[[4-[(1-Methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
- 5-{4-[(1-Methylcyclohexyl)Methoxy]Benzyl}-1,3-Thiazolidine-2,4-Dione
- Add 3878
- Ciglitazona
- Ciglitazona [Spanish]
- Ciglitazone [USAN:INN]
- Ciglitazonum
- Ver más sinónimos
- Ciglitazonum [Latin]
- U 63287
- Unii-U8Qxs1Wu8G
Ciglitazone is a drug that belongs to the class of non-steroidal anti-inflammatory drugs, which are used to treat pain and inflammation. It has been shown to reduce the production of reactive oxygen species in rat hippocampal neurons. Ciglitazone has also been reported as an oral hypoglycaemic agent, which may be due to its ability to inhibit phosphoenolpyruvate carboxykinase (PEPCK). Ciglitazone inhibits toll-like receptor 4 (TLR4) activation and TLR4-induced pparγ transcriptional activity, which may be beneficial in the treatment of skin cancers such as squamous cell carcinoma.
Ciglitazone has shown biocompatibility with melanoma cells and has been investigated for use as a scaffold material for tissue engineering applications.